Paul A. Hopper
Executive chairman
Biotechnology
Imugene
Australia
Biography
Paul A. Hopper (born 1956) is an Australian bioentrepreneur who has been associated since 2003 with a number of biotechnology companies, most of them publicly traded. Hopper returned to Australia in 2014 in order to further develop a number of biotechnology companies of which was an executive. Hopper is currently on the board of three ASX-listed companies: Imugene (ASX: IMU, Executive chairman), a cancer immunotherapy company which he joined as a director in October 2012 and which he helped structure in its present form in 2013, becoming Executive chairman in December of that year. Viralytics (ASX: VLA, Non-Executive chairman), a company currently developing an oncolytic virus where Hopper has been a director since September 2008 and chairman since November 2008. Prescient Therapeutics (ASX: PTX, Executive Director), a small molecule drug developer focused on cancer where Hopper has been a director since May 2014.
Research Interest
Cancer immunotherapy, Oncolytic virus
